The first vaccine to combine both PCV2a and PCV2d antigens in a single dose designed for optimized herd health is launching in the U.S. on Sept. 3.
INGELVAC CIRCOFLEX AD, a new vaccine from Boehringer Ingelheim, targets porcine circovirus 2 (PCV2), one of the most prevalent and economically significant viruses in swine production.
Porcine circovirus associated disease (PCVAD) is caused by the PCV2 virus and can lead to severe weight loss, diarrhea and difficulty breathing. Not only does it impair the immune system, but it enhances co-infections and leaves pigs more susceptible to other swine diseases affecting the respiratory, reproductive and digestive systems.
A Shift Over Time
Several genotypes have been identified, but experts have seen a clear shift over the past decade, with PCV2d becoming the predominant genotype in the U.S. and throughout the world.
Boehringer Ingelheim says the broad protection provided by INGELVAC CIRCOFLEX AD was “designed with this shifting landscape in mind, advancing pig health and sustaining viable businesses for producers.”
“With INGELVAC CIRCOFLEX AD, we’re further advancing protection against evolving PCV2 threats with both PCV2a and PCV2d antigens combined. These two genotypes are responsible for over 90% of clinical cases, and we are the first company to offer both antigens in a single dose,” said Gerard Ensink, global head of swine at Boehringer Ingelheim, in a news release. “We’ll continue to closely monitor PCV2 and other diseases impacting pig performance to help producers stay ahead of emerging risks.”
To be effective controlling PCV2, Boehringer Ingelheim says vaccines must provide broad cross protection. Experts also say it is important to manage co-infections, implement strong biosecurity measures and maintain a thorough understanding of disease epidemiology.
“We’re excited to bring INGELVAC CIRCOFLEX AD to the U.S. market first, delivering the latest innovation in PCV2 protection,” said Steve Boren, vice president, U.S. livestock at Boehringer Ingelheim, in the release. “In an industry where disease is a constant challenge, this next-generation vaccine offers broader, safer, longer-lasting immunity against the most prevalent PCV2 genotypes and can help proactively strengthen a herd’s immune system to reduce the risk and impact of co-infections.”
What Does the Label Say?
INGELVAC CIRCOFLEX AD is approved for use in healthy pigs as early as two weeks of age. The vaccine should be administered intramuscularly via a single, 1 mL dose, with onset of immunity two weeks post-vaccination and a duration of immunity of at least six months, the label says.
“The vaccine includes Boehringer’s trusted water-based IMPRANFLEX adjuvant,” the release says. “It helps contribute to a robust immune response and limits the risk of injection-site reactions for safe, efficacious delivery of next-generation PCV2 protection.”
This vaccine is available in 50-dose and 250-dose presentations. Learn more here.
